Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 2Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 12Purpura 1Paraproteinemias 1Neoplasms 1Nausea 1Natural Killer/T-cell Lymphoma 1Macroglossia 1Lymphoproliferative Disorders 1Lymphadenopathy 1Immunoproliferative Disorders 1Immunoglobulin Light-chain Amyloidosis 1Hepatomegaly 1Hematologic Neoplasms 1Gastrointestinal Hemorrhage 1Diarrhea 1Constipation 1

Interventions

Bortezomib 5Dexamethasone 4Lenalidomide 3Granulocyte Colony-Stimulating Factor 3fludarabine 2filanesib 2dacetuzumab 2Steroids 2Injections, Subcutaneous 2Filgrastim 2plerixafor 1ofatumumab 1isatuximab 1fludarabine phosphate 1ficlatuzumab 1birtamimab 1Zoledronic Acid 1Whole-Body Irradiation 1Vorinostat 1Tacrolimus 1Rifaximin 1Proteasome Inhibitors 1Plasma Exchange 1Mycophenolic Acid 1KW-2478 1Hsp90 inhibitor KU757 1Erlotinib Hydrochloride 1Denosumab 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Paraproteinemias × isatuximab × Clear all
NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡